21-Gene Recurrence Assay Associated With Favorable Metabolic Profiles in HR-Positive, HER2-Negative Early-Stage Breast Cancer Patients.
Biomarkers
/ blood
Biomarkers, Tumor
/ genetics
Blood Glucose
/ analysis
Body Mass Index
Breast Neoplasms
/ genetics
Cholesterol, HDL
/ blood
Female
Follow-Up Studies
Gene Expression Profiling
Glycated Hemoglobin
/ analysis
Humans
Insulin
/ blood
Insulin Resistance
Insulin-Like Growth Factor I
Metabolome
Middle Aged
Neoplasm Recurrence, Local
/ genetics
Prognosis
Receptor, ErbB-2
/ metabolism
Receptors, Estrogen
/ metabolism
Receptors, Progesterone
/ metabolism
21-gene recurrence score assay
Chinese women
breast cancer
cancer-related genes
metabolic profile
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2021
2021
Historique:
received:
15
06
2021
accepted:
12
07
2021
entrez:
30
8
2021
pubmed:
31
8
2021
medline:
12
2
2022
Statut:
epublish
Résumé
Comprehensive investigations of the associations between 21-gene recurrence assay and metabolic profiles in Chinese breast cancer patients are limited. We evaluated the relations of the 21-gene recurrence risk score (RS) and the expression of cancer-related genes with metabolic factors and biomarkers of insulin and the insulin-like growth factor (IGF) axis, and examined the interactions between the 21-gene RS and these metabolic profiles on breast cancer recurrence in Chinese women with HR-positive, HER2-negative early-stage breast cancer. The 21-gene RS was inversely associated with body mass index ([BMI]β: -0.178 kg/m The 21-gene RS was related to favorable metabolic profiles including lower BMI, HOMA-IR, insulin, and C-peptide, and higher HDL in Chinese breast cancer patients, and its prognostic impact on breast cancer recurrence was more likely to present among patients with relatively favorable metabolic profiles.
Sections du résumé
Background
Comprehensive investigations of the associations between 21-gene recurrence assay and metabolic profiles in Chinese breast cancer patients are limited.
Methods
We evaluated the relations of the 21-gene recurrence risk score (RS) and the expression of cancer-related genes with metabolic factors and biomarkers of insulin and the insulin-like growth factor (IGF) axis, and examined the interactions between the 21-gene RS and these metabolic profiles on breast cancer recurrence in Chinese women with HR-positive, HER2-negative early-stage breast cancer.
Results
The 21-gene RS was inversely associated with body mass index ([BMI]β: -0.178 kg/m
Conclusions
The 21-gene RS was related to favorable metabolic profiles including lower BMI, HOMA-IR, insulin, and C-peptide, and higher HDL in Chinese breast cancer patients, and its prognostic impact on breast cancer recurrence was more likely to present among patients with relatively favorable metabolic profiles.
Identifiants
pubmed: 34456877
doi: 10.3389/fendo.2021.725161
pmc: PMC8385488
doi:
Substances chimiques
Biomarkers
0
Biomarkers, Tumor
0
Blood Glucose
0
Cholesterol, HDL
0
Glycated Hemoglobin A
0
IGF1 protein, human
0
Insulin
0
Receptors, Estrogen
0
Receptors, Progesterone
0
hemoglobin A1c protein, human
0
Insulin-Like Growth Factor I
67763-96-6
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
725161Informations de copyright
Copyright © 2021 Zhu, Wang, Tong, Chen and Shen.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
N Engl J Med. 2004 Dec 30;351(27):2817-26
pubmed: 15591335
J Clin Oncol. 2007 May 20;25(15):2127-32
pubmed: 17513820
J Clin Oncol. 2020 Mar 1;38(7):725-733
pubmed: 31809240
Int J Cancer. 2019 Aug 15;145(4):882-893
pubmed: 30653259
N Engl J Med. 2015 Nov 19;373(21):2005-14
pubmed: 26412349
BMC Cancer. 2018 May 4;18(1):526
pubmed: 29728098
N Engl J Med. 2019 Jun 20;380(25):2395-2405
pubmed: 31157962
Breast Cancer Res Treat. 2016 Jun;157(3):597-603
pubmed: 27271766
Oncotarget. 2017 Jun 13;8(24):38706-38716
pubmed: 28404972
Nat Rev Cancer. 2008 Dec;8(12):915-28
pubmed: 19029956
J Clin Oncol. 2016 Jul 1;34(19):2221-31
pubmed: 27044936
J Clin Oncol. 2016 Dec 10;34(35):4270-4276
pubmed: 27903155
Ann Oncol. 2013 Sep;24(9):2206-23
pubmed: 23917950
Clin Cancer Res. 2016 May 1;22(9):2283-9
pubmed: 26712688
J Clin Oncol. 2006 Aug 10;24(23):3726-34
pubmed: 16720680
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Int J Cancer. 2006 Jul 1;119(1):236-8
pubmed: 16450399
Trends Endocrinol Metab. 2010 Oct;21(10):610-8
pubmed: 20663687
Semin Cancer Biol. 2020 Feb;60:274-284
pubmed: 31491560
Diabetologia. 2012 Oct;55(10):2811-2822
pubmed: 22798065
Front Oncol. 2020 Aug 19;10:1384
pubmed: 32974138
Surg Oncol. 2020 Sep;34:74-79
pubmed: 32891357
Onco Targets Ther. 2020 Aug 11;13:8027-8036
pubmed: 32848423
J Cancer. 2016 Nov 26;7(15):2346-2359
pubmed: 27994674
Lancet Oncol. 2010 Jan;11(1):55-65
pubmed: 20005174
Mol Cancer. 2015 Feb 15;14:43
pubmed: 25743390
Front Oncol. 2021 Mar 26;11:619840
pubmed: 33842323
J Clin Oncol. 2002 Jan 1;20(1):42-51
pubmed: 11773152